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Abstract
BACKGROUND: Microcephaly with or without chorioretinopathy, lymphedema,
or mental retardation syndrome (MCLMR) is a rare autosomal dominant disorder
with variable expressivity. It is characterized by mild-to-severe microcephaly,
often associated with intellectual disability, ocular defects and lymphedema. It
can be sporadic or inherited. Eighty-seven patients have been described to
carry a mutation in KIF11, which encodes a homotetrameric motor kinesin, EG5.
METHODS: We tested 23 unreported MCLMR index patients for KIF11. We also
reviewed the clinical phenotypes of all our patients as well as of those described in
previously published studies. RESULTS: We identified 14 mutations, 12 of which
are novel. We detected mutations in 12 affected individuals, from 6 out of 6 familial
cases, and in 8 out of 17 sporadic patients. Phenotypic evaluation of patients (our
26 + 61 earlier published = 87) revealed microcephaly in 91%, eye anomalies in
72%, intellectual disability in 67% and ...
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 Key Points 
•  Careful patient examination for all signs and 
symptoms is important for precise clinical 
diagnosis. 
•  Primary lymphedema has a high underlying 
genetic heterogeneity. Currently, 20 genes are 
implicated. 
•  Neonatal edema, including non-immune 
hydrops fetalis, can also be caused by muta-
tions in some of these genes. 
•  Genetic predisposing factors are unknown for 
a large fraction of patients. 
•  There is large variability in clinical expressiv-
ity and often incomplete penetrance for all 
signs and symptoms. 
•  Panel-based targeted next-generation sequenc-
ing is the most effi cient approach for diagnos-
tic screens. 
•  Secondary lymphedema may be infl uenced by 
genetic predisposition. 
 Introduction 
 Lymphedema is known since the middle of the 
nineteenth century, yet the fi rst genes associated 
with this condition have been discovered only in 
the twenty-fi rst century. Since then, more than 
20 genes have been linked to the development of 
primary lymphedema. Originally discovered 
using linkage analysis in large families or animal 
models, the more recent approach using Next- 
Generation Sequencing (NGS) has allowed to 
discover genes using smaller families and even 
sporadic cases. In parallel, detailed in vitro and 
in vivo studies on molecular and cellular mecha-
nisms involved in lymphangiogenesis have unrav-
eled numerous novel functional candidate genes. 
 Primary lymphedema can be present as an 
inherited or a sporadic trait. It can be dominant, 
recessive (with consanguinity or not), or linked to 
the X-chromosome. There is important heteroge-
neity in the clinical appearance of lymphedema. 
Primary lymphedema can be the unique sign, 
affect different parts of the body (limb(s), arms, 
hands, head and neck, abdomen, etc.), be unilat-
eral or bilateral, and appear at different ages at 
onset. It can also be part of a complex syndrome, 
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some of which are very rare, with only few cases 
reported. 
 Our current knowledge on the environmental 
and genetic variability as the cause of primary 
lymphedema is limited. Most of the Mendelian 
mutations have been identifi ed in a limited num-
ber of patients or even only few families used in 
the original linkage study, several of the genes 
have been identifi ed very recently limiting the 
time they have been used in clinical setting for 
diagnostic screening, the number of patients 
screened in reports is often very limited, and 
most screens have been done on gene-by-gene 
basis. Moreover, some of the clinical signs may 
be missed, and thus, the clinical classifi cation is 
not necessarily correct. This renders it diffi cult to 
have a representative and a comprehensive over-
view of the current state of the art. 
 In this chapter, we make an extensive review 
of the medical literature. Clinical data was col-
lected for all patients with a proven mutation, 
taking into account each mentioned sign and 
symptom. In the presentation, we divide the 
genes (and associated lymphedemas) into two 
groups. The fi rst category includes the genes that 
cause lymphedema as the major sign, which is 
also the reason for medical consultation 
(Table  3.1 ). The second group contains the genes 
that are related to a usually well-known syn-
drome and for which lymphedema is minor sign 
(Table  3.2 ). Only a quarter of all cases are 
explained by mutations within the 20 genes. It 
appears that the historical classifi cation based on 
the age of onset, i.e., congenital (at birth or early 
in life), praecox (teenage years), and tarda (late in 
life) is becoming irrelevant, as this does not cor-
relate with the genetic background. Instead, the 
clinical presentation of the signs and symptoms 
can be helpful to associate the primary lymph-
edema to the most likely causative gene.
 Lymphedema as a Major Sign 
 Phenotype of Patients 
 Lymphedema is the major sign for 14 of the 
genes currently known to cause primary lymph-
edema when mutated. The penetrance of lymph-
edema is though often incomplete, i.e., even 
though an individual carries a familial mutation, 
(s)he does not necessarily have lymphedema. 
This is also true for the other associated signs and 
symptoms listed in Table  3.1 . 
 The cardiovascular system is often affected; 
varicose veins are not infrequent. Hydrocele can 
be present in at least four of the entities 
(Table  3.1 ). In the nervous system, symptoms 
range from hearing loss to learning diffi culties 
and macrocephaly. Cutaneous and subcutaneous 
symptoms are frequent, including infection, pap-
illomas, and cellulitis, many of which are consid-
ered secondary. Yet there are subtype-specifi c 
differences in prevalence (Table  3.1 ). In the mus-
culoskeletal system, syndactyly or camptodac-
tyly is observed. Mutations in GATA2 affect the 
respiratory system, generating pulmonary alveo-
lar proteinosis. Mutations in GATA2, as well as 
IKBKG, also predispose to severe infections. 
Involvement of the digestive system is relatively 
rare (GJC2 and IKBKG), and renal abnormalities 
have been reported only in some cases (VEGFR3, 
FOXC2, and SOX18). Patients with a GATA2 
mutation have a susceptibility to hematologic 
malignancies. 
 Genetic Differential Diagnosis: Which 
Gene to Screen? 
 The unraveled high genetic heterogeneity in pri-
mary lymphedema has resulted in a high number 
of clinical subcategories. Currently 21 geneti-
cally defi ned subgroups, as well as the subgroup 
of undefi ned ones, exist. Moreover, the latter 
mostly likely involves several genes. Some of the 
genetically defi ned 21 subgroups have typical 
signs, the presence of which can help in clinical 
diagnosis. In addition, familial history (Table  3.3 ) 
is an important factor in determining candidate 
genes for diagnostic screens.
 The “unique” signs, i.e., those specifi c to one 
or two genes, are variable. Isolated lower limb 
lymphedema present at birth (the classic presen-
tation of Milroy disease) suggests a FLT4/
VEGFR3 (FMS-like tyrosine kinase 4/vascular 
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endothelial growth factor receptor 3) or VEGFC 
(vascular endothelial growth factor C) mutation. 
For VEGFR3, the intracellular part is most fre-
quently mutated and should be sequenced fi rst 
(exons 17–25), whereas any part of the VEGFC 
coding sequence can be mutated. Functional 
aplasia of the lymphatic vessels (failure of initial 
lymphatic absorption) in lymphoscintigraphy 
underscores the clinical diagnosis of VEGFR3 
mutation. Patients with a mutation in VEGFC 
have reduced uptake with tortuous lymphatic 
tracts and evidence of rerouting [ 1 – 3 ]. 
 When a patient has distichiasis (double rows 
of eyelashes, which is not always easy to notice) 
and lower limb lymphedema, the likely candidate 
is FOXC2 (forkhead box C2). The lymphedema 
is often of late onset, even if some patients with 
congenital lymphedema or hydrops fetalis have 
been described [ 4 ]. The presence of a cleft lip 
and/or palate also guide towards this gene. 
Individuals with FOXC2 mutation demonstrate 
refl ux of lymph within the lower limbs as a result 
of valve failure within the hyperplastic lymphatic 
vessels [ 3 ]. 
 Patients with lymphedema on all four extrem-
ities, whether early or late onset, evoke GJC2 
(gap junction protein gamma-2) [ 5 ]. In lymphos-
cintigraphy, lymphatic tracts appear normal, but 
with a signifi cant reduction in absorption by 
peripheral lymphatics in all four limbs [ 3 ]. 
Mutations in another gap junction protein GJA1 
(gap junction protein alpha-1) have been found in 
patients with lymphedema and, among other 
signs, microdontia; a syndrome known as oculo-
dentodigital dysplasia. The patient had clear 
lower limb lymphedema and subclinical upper 
limb lymphedema by lymphoscintigraphy [ 6 ]. 
 Microcephaly can be helpful as a sign for differ-
ential diagnosis. Within the genetically defi ned 
groups, it is described, as a major sign, in patients 
with a mutation in KIF11 (kinesin family member 
11). This phenotype combines microcephaly with or 
without chorioretinopathy, lymphedema, and intel-
lectual disability into a syndrome, abbreviated as 
MCLMR. Microcephaly is present in 91 % (68/75) 
of the patients and two other major signs, intellec-
tual disability and eye anomalies, both in 69 % of 
the patients (MJ Schlögel, Submitted). As for 
VEGFR3, failure of initial lymphatic absorption is 
observed in lymphoscintigraphy [ 3 ]. 
 Facing a patient with microcephaly, 4-limb 
lymphedema and “unusual face” suggests 
CCBE1 (collagen and calcium-binding EGF 
domain-containing protein 1) and FAT4 (homo-
log of drosophila FAT tumor suppressor 4) as the 
mutated gene. This entity is known as the lymph-
edema–intestinal lymphangiectasia–intellectual 
disability syndrome or the Hennekam syndrome. 
There is no family history, or history is sugges-
tive of recessive inheritance. The patient can be 
homozygous or compound heterozygous for the 
mutation(s) [ 7 ]. In one patient with a mutation in 
CCBE1, abnormal drainage in the upper and 
lower limbs, and the thoracic duct, was observed 
in lymphoscintigraphy [ 3 ]. 
 GATA2 (gata-binding protein 2) and IKBKG 
(inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase gamma) are associ-
ated with severe immunological problems. 
Patients with a GATA2 mutation develop warts, 
and viral and/or bacterial infections [ 8 ]. 
Lymphoscintigraphy reveals hypoplasia of 
 lymphatics within the affected lower limbs [ 3 ]. 
Similar features, as well as ectodermal dysplasia, 
are seen in patients mutated for IKBKG [ 9 ]. It is 
important to note that GATA2 predisposes to sev-
eral cancers. This syndrome is known as primary 
lymphedema with myelodysplasia or Emberger 
syndrome. 
 There are some additional rare associations. 
In one family, lymphedema was associated 
with choanal atresia, and the affected individuals 
had a partial deletion (exons 7) in  PTPN14 
(protein- tyrosine phosphatase nonreceptor-type 
14) [ 10 ]. Another rare syndrome combines 
lymphedema with hypotrichosis and telangiecta-
sias (HLT = Hypotrichosis–lymphedema–telangi-
ectasia). It is caused by dominant or recessive 
mutations in SOX18 (SRY-Box 18) [ 11 ]. A par-
ticular stop codon in this gene causes severe 
 glomerulonephritis leading to end-stage renal 
disease necessitating renal transplantation [ 12 ]. 
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 Lymphedema as a Minor Sign 
 In some well-known syndromes, such as tuber-
ous sclerosis, Noonan syndrome and Turner syn-
drome, lymphedema can be present, although the 
diagnosis is made on the basis of other signs and 
symptoms. In some syndromes, such as in capil-
lary malformation–arteriovenous malformation 
or CM-AVM, presence of lymphedema is only 
rarely reported, and/or it is subclinical, and thus 
not systematically looked for. Therefore, preva-
lence fi gures are only weak estimates. These 
genes are presented in Table  3.2 . 
 Tuberous Sclerosis 1 and 2 
 Tuberous sclerosis (TSC) is an autosomal domi-
nant disease characterized by hamartomas in dif-
ferent organ systems (skin, brain, heart, etc.). TSC 
affects between 1/6.000 and 1/10.000 individuals 
[ 13 ]. Compared to patients with a TSC1 mutation, 
those with a TSC2 mutation are more likely to 
have partial epilepsy, complex partial seizures, 
infantile spasms, subependymal giant- cell astro-
cytomas, and intellectual disability. Dental pits 
are often noted (Table  3.2 ). Primary lymphedema 
is present in less than 10 % of the cases. 
 Noonan Syndrome 
 Noonan syndrome (NS) is usually considered as 
a clinical diagnosis on the basis of the “typical 
face,” including a broad forehead, hypertelorism, 
down-slanting palpebral fi ssures, ptosis, a high- 
arched palate, and low-set and posteriorly rotated 
ears. Cardiac anomalies and cryptorchidism can 
also be present. Mutations in PTPN11, SOS1, 
RAF1, KRAS, NRAS, SHOC2, or CBL cause 
this syndrome [ 14 ]. The overall incidence of 
lymphatic manifestations among NS is estimated 
to be ~20 % [ 15 ]. Lymphedema has only been 
reported in patients with a mutation in PTPN11, 
SOS1, or KRAS; thus, only these subtypes are 
included in Table  3.2 . With enlarged screens it 
may become evident that the other genetic sub-
types can also be associated with lymphedema. 
Patients with RAF1 (Raf-1 proto-oncogene, ser-
ine/threonine kinase) mutation have been 
reported with lymphangiectasia or microkystic 
lymphatic malformation. The Costello syndrome, 
caused by KRAS (Kirsten rat sarcoma viral onco-
gene homolog) mutations, shares many features 
with Noonan syndrome and patients can also 
present lymphatic anomalies. Patients with a 
PTPN11 (protein tyrosine phosphatase, non- 
receptor type 11) mutation could have thrombo-
cytopenia, while mutations in SOS1 (son of 
sevenless homolog 1) or KRAS seem to com-
monly cause macrocephaly. 
 Turner Syndrome 
 Turner syndrome occurs in 1/2.500–1/3.000 live- 
born girls. About 50 % have monosomy X (45,X), 
and 5–10 % have a duplication of the long arm of 
one X (46,X,i(Xq)). Most of the rest are mosaic 
for 45,X [ 16 ]. The main signs are mental retarda-
tion, cardiac disease, renal malformation, short 
stature, and edema (puffy hands and feet, and 
redundant nuchal skin). Most cases of Turner 
syndrome are diagnosed prenatally, by the pres-
ence of edema. Karyotype can easily reveal the 
genetic defect in most cases. 
 Capillary Malformation–
Arteriovenous Malformation 
Syndrome 
 Heterozygous mutations in  RASA1 (RAS p21 
protein activator 1) cause multiple capillary mal-
formations (CM) associated with fast-fl ow vas-
cular malformations (CM-AVM). There is high 
intrafamilial phenotypic variability. Almost all 
patients with a RASA1 mutation have one or 
more capillary malformations (97 %) and 23 % 
have also a fast-fl ow lesion [ 17 ]. In a few patients 
with Parkes Weber syndrome and a RASA1 
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mutation, primary lymphedema is also present 
[ 18 ]. As for the other syndromes in this subclass, 
the signs of CM-AVM lead to the correct differ-
ential diagnosis. 
 Approach for Genetic Screening 
 Most diagnostic genetic tests have relied on 
Sanger sequencing of the exonic parts of a given 
candidate gene. When more than one possible 
candidate gene exists, a sequential approach has 
classically been used, starting with the gene that 
most often is mutated in the given clinical sub-
type. The high genetic heterogeneity within 
patients with primary lymphedema (so far 20 
“candidate” genes) renders this approach time- 
consuming and labor intense. Only precise clini-
cal diagnosis can help target the correct gene. Yet 
the incomplete penetrance of the associated signs 
and symptoms, and the high frequency of de novo 
cases for some of the genes may make differential 
diagnosis impossible. Targeted high- throughput 
sequencing now allows to screen several genes at 
a time using panels. This is replacing the sequen-
tial method. The panel approach allows the clini-
cian to obtain results for multiple genes at once, 
which in turn helps in clinical diagnosis, even in 
the absence of associated symptoms. 
 Prenatal Testing 
 Many signs and symptoms associated with a 
mutation in the 20 genes and monosomy X are 
detectable only after birth. Thus, differential 
diagnosis is even more diffi cult in the prenatal 
period. Fetal edema may appear as nuchal edema, 
ascites, pleural effusion, chylothorax, pericardial 
effusion, cutaneous edema, or hydrops fetalis. 
These can be caused by mutations in VEGFR3, 
FOXC2, CCBE1, RASA1, PTPN11, and SOS1, 
and Monosomy X. In families at risk for lymph-
edema, detailed morphological ultrasound should 
be carried out paying attention to the signs in 
Tables  3.1 and  3.2 . It is also important to search 
for familial history of the various signs, as they 
could help establish the correct differential diag-
nosis. The usefulness of the novel panel approach 
is particularly appreciated for prenatal genetic 
testing due to its completeness and rapidity. 
 Genetic Counseling 
 Diagnostic Genetic Testing 
 The identifi cation of a mutation in one of the 
known genes allows more precise structure of the 
follow-up for the patient, especially regarding the 
signs and symptoms that develop with time. For 
example, myelodysplasia is not present at birth 
and necessitates a careful monitoring in patients 
with a GATA2 mutation (Table  3.1 ). Genetic 
counseling for risk calculation and prenatal 
genetic testing also become possible via the iden-
tifi cation of the causative genetic mutation. 
 Despite an increased number of genes involved 
in lymphangiogenesis and/or in the etiology of 
primary lymphedema, a large proportion of 
lymphedema patients still remain unexplained 
after diagnostic genetic testing. Based on the 
analysis of more than 400 index patients, muta-
tions in the known genes only explain about one 
third of the patients [ 19 ]. It could be that some of 
the mutations in these genes go undetected, as 
they are not in the parts that are classically 
screened (i.e., the exons) or they are not detected 
by the methods used. These could be intronic or 
promoter mutations, or large deletions or inser-
tions. They would likely not explain the majority 
of the unexplained patients. Thus, additional 
genes should exist. 
 Genetic diagnosis is important to advance our 
knowledge on primary lymphedema. Precise sub-
classifi cation on the basis of genetic data is 
needed to better defi ne the patient groups for 
genotype–phenotype correlations. Prognosis 
may also differ between the subgroups. Moreover, 
targeted therapies are best developed on detailed 
comprehension on the underlying pathophysio-
logical mechanisms. 
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 Next-Generation Sequencing 
and the Usefulness of a Panel-Based 
Approach 
 During the past few years, Next-Generation 
Sequencing (NGS) has opened a new era for 
mutation screens. Whole-exome sequencing 
(WES) allows to screen all the coding exons of the 
human genome in one experiment. However, not 
all genes are equally well covered. This may be 
due to for example inequalities in exome capture 
and diffi culty in amplifying areas rich in G and C 
nucleotides. Moreover, the cost and ethical issues 
limit the WES approach in clinical settings. 
 Another interesting approach is targeted next- 
generation sequencing. This is based on capture 
or amplifi cation of a certain, much more limited, 
number of exons from the human genome. For 
example, the 20 known “lymphedema genes” 
cover a total target size of around 117 kb. With a 
specifi cally designed panel, they can be analyzed 
in one experiment for a given patient often for a 
similar prize as a single gene screen using Sanger 
sequencing. For the Noonan syndrome, a study 
shows a sixfold reduction in cost using a 
RASopathy panel with a target area of 30 kb [ 20 ]. 
Therefore, it can be used as a primary genetic 
screen, which does not need a fi nalized, detailed 
clinical diagnosis to be effi cient. The value of this 
technique also lies in its rapidity. Thus, genetic 
results do not only confi rm a clinical diagnosis 
but help, in a timely manner, to establish it. 
 How to Identify the Causative Variant? 
 The Sanger-sequencing-based monogenic 
screens often reveal one probably pathogenic 
variant in one gene. If no such variant is identi-
fi ed, screening of a second gene is started. When 
a “causative mutation” is identifi ed, screens are 
stopped. This differs fundamentally from the tar-
geted NGS approach, which renders data avail-
able on all targeted genes at once. Thus, hundreds 
of variants can be analyzed at the same time, not 
limited to a single gene only. This allows to study 
possible interacting variants between the screened 
genes. However, software in diagnostic routine 
cannot address this question. Moreover, identifi -
cation of even the monogenic disease-causing 
mutation(s) is not without caveats, as it is often 
diffi cult to make the distinction between an 
amino acid changing polymorphism and a 
disease- causing mutation. 
 Co-segregation analysis of the identifi ed 
changes within the family can give further proof 
for the implication of a given nucleotide change. 
This can be done using classic Sanger sequenc-
ing. Alternatively, several family members may 
be sequenced in parallel using a panel approach. 
 To predict the impact of a mutation at the pro-
tein level, different tools based on evolutionary 
conservation, structural constraints, or chemical 
qualities of the protein with the changed and 
unchanged amino acids have been developed. 
Moreover, databases, such as dbSNP ( http://
www.ncb i .n lm.n ih .gov /pro jec t s /SNP/  ) , 
1000Genomes ( http://browser.1000genomes.org/
index.html ), and GoNL ( http://www.nlgenome.
nl/search/ ), collect reference sequence variants 
(most of which are polymorphisms) from differ-
ent populations. These can be used to fi lter out 
known polymorphisms. In contrast, the absence, 
or a low allele frequency indicates that the variant 
is rare and may have a deleterious impact on the 
protein function. Other databases, such as HGMD 
( www.hgmd.org ), regroup the known mutations 
in most genes, including small changes (Single 
Nucleotide Changes, Multiple Nucleotide 
Changes, insertions, and deletions) and larger 
structural variations, such as chromosomal 
 deletions, insertions, or amplifi cations. 
 Even with these tools, many identifi ed vari-
ants are reported as having “an unknown signifi -
cance.” For these, tests for in vitro and in vivo 
functional analysis would need to be developed. 
This is time-consuming and out of scope for rou-
tine diagnostic laboratories. 
 The Lymphedema-Causing Proteins 
 The genes that harbor mutations causing pri-
mary lymphedema and especially the proteins 
they encode can be grouped around the 
VEGFC–VEGFR3 ligand–receptor signaling 
complex and the downstream signaling pathways 
via PI3Kinase-AKT and MAPK [ 21 ]. 
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 VEGFC–VEGFR3 Axis 
 VEGFR3 was the fi rst protein found to be mutated 
in primary lymphedema patients and the VEGFC–
VEGFR3 signaling pathway is a major regulator 
of lymphangiogenesis. VEGFC and PTPN14 
interact directly with VEGFR3. CCBE1 increases 
the capacity of VEGFC to activate VEGFR3 
phosphorylation. Downstream of this complex, 
activation of the transcription factor FOXC2 
ensues. GATA2 also regulates the expression 
of FOXC2, which plays a major role in the 
 development of valves in lymphatic vessels by 
regulating the expression of connexin CX47/
GJC2. Connexin, CX43/GJA1 is enriched on 
the upstream side of the lymphatic valves. 
Phosphorylation of FOXC2 is also linked to the 
expression of KIF11 [ 22 ]. The transcription factor 
SOX18 regulates PROX1 (prospero homeobox 
1), a main factor for lymphangiogenesis, which 
regulates ITGA9, another valvular protein. So far, 
there is no clear link between VEGFR3 and FAT4, 
but the latter is regulated by the miRNA MIR31, 
linked to lymphangiogenesis [ 23 ]. 
 Ras/MAPK Axis 
 Another major signaling pathway associated with 
lymphedema is the RAS-MAPK pathway. 
Mutations in this family of proteins can cause 
RASopathies. Mutations in each component of 
the pathway cause a distinct disease, but all the 
RASopathies share common features, such as 
craniofacial dysmorphology and cardiac malfor-
mations [ 14 ]. The pathway is involved in cell 
cycle, cellular growth, differentiation and senes-
cence. The activation of the pathway can come 
from a membrane receptor that upon activation 
binds adaptors (PTPN11/SHP2, SOS1, and 
RASA1), which increase the proportion of the 
active form of a RAS protein (KRAS, HRAS). 
The activated RAS is able to activate the MAPK 
(RAF1) signaling cascade. The MAPK phos-
phorylates, among others, TSC1 and TSC2, and 
inhibits their function [ 24 ]. 
 Therapeutic Targets 
 To date, no curative treatment exists for primary 
lymphedema. Symptomatic alleviation can be 
achieved by lymphatic drainage, elastic compres-
sion, and debulking surgery. The risk of infection 
is not negligible and should also be adequately 
managed. The numerous associated clinical fea-
tures require their specifi c management. 
 Alternative treatments are being developed. 
Sorafenib, a tyrosine kinase inhibitor used in 
selected cancers, decreases vascular permeability 
by suppressing VEGFRs, and it is in a clinical 
trial for secondary lymphedema [ 25 ]. Another 
ongoing trial combines autologous lymph node 
grafts with adenoviral expression of VEGF-C 
[ 26 ]. It seems to improve the connectivity of the 
graft with the lymphatic system. Animal models 
are also developed and used to test inventive ther-
apies. Plasmid-based expression of Hepatocyte 
growth factor (HGF) in rat-tail or in mice with 
induced upper limb edema inhibits the growth of 
swelling and lymphangiogenesis [ 27 ]. As there is 
high genetic heterogeneity within the causes of 
primary lymphedema, it would be interesting to 
identify if there is any common pathologic 
molecular alteration. This would allow a more 
general, targeted therapy, to be developed. For 
example, if the RAS/MAPK pathway would be 
altered in various patients in similar fashion inde-
pendent of the underlying causative gene, mole-
cules developed to treat cancer could be used for 
RASopathies and primary lymphedema [ 14 ]. 
 Secondary Lymphedema 
 Secondary lymphedema is the most common 
form of lymphedema. It may be caused for exam-
ple by infection, surgery, radiation, or injury. 
Secondary lymphedema occurs in approximately 
30 % of breast cancer patients who undergo sur-
gery or irradiation. Risk factors include the extent 
of surgery and irradiation, disease related factors 
(stage at diagnosis, pathological nodal status, and 
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number of dissected lymph node), and patient- 
related factors (age at diagnosis, body mass 
index, and presence of a sedentary lifestyle). A 
study suggests a link between germline muta-
tions in CX47/GJC2 and the occurrence of sec-
ondary lymphedema [ 28 ]. Another study 
genotyped 155 patients and 387 controls without 
lymphedema for 17 candidate genes (including 
FOXC2, HGF, VEGFC, and VEGFR3, but not 
GJC2) [ 29 ]. A signifi cant association was found 
with LCP2 (lymphocyte cytosolic protein 2), 
NRP2 (neuropilin 2), SYK (spleen tyrosine 
kinase), VCAM1 (vascular cell adhesion mole-
cule 1), FOXC2, and VEGFC. However, other 
studies are needed to confi rm the signifi cance of 
these associations and to identify the nucleotide 
changes that are causative for the predisposition. 
 Conclusion 
 Although more than 20 genes have been found to 
be mutated in patients with primary lymphedema, 
they explain less than a third of all cases. 
However, all the 20 genes have never been 
exhaustively screened for any patient cohort, and 
the respective prevalences are likely underesti-
mated. Moreover, detailed genotype–phenotype 
correlation studies have not been exhaustive, 
especially when lymphedema was not the major 
feature of the disease/syndrome. Although it 
remains important to look for all additional signs 
to orient diagnosis, the targeted panel approach, 
which allows to obtain results for all known 
genes at ones, will greatly help primary diagnosis 
and genotype–phenotype correlation studies. 
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